What Pfizer Canada, Inc does

Pfizer Canada ULC is the wholly-owned Canadian subsidiary of Pfizer Inc. (NYSE: PFE), one of the world's largest biopharmaceutical companies, and was founded in 1951 with its current head office in Kirkland, Quebec (West Island of Montreal) since 1975. The company commercializes a diversified healthcare portfolio spanning prescription medicines and vaccines across oncology (PADCEV for bladder cancer, BRAFTOVI for BRAF V600E metastatic colorectal cancer and melanoma), infectious disease (COVID-19 vaccines including the Omicron KP.2 variant-adapted formulation with BioNTech, ABRYSVO for RSV), women's health (the PREMARIN family of conjugated estrogens, DUAVEE, DUAVIVE), cardiovascular, inflammatory conditions, and rare diseases. Its core technology footprint includes antibody-drug conjugates (PADCEV), small-molecule BRAF inhibitors (BRAFTOVI), the Pfizer-BioNTech mRNA vaccine platform, and a specialized manufacturing capability for conjugated estrogens at its Brandon, Manitoba facility, which serves as the global production site for the active pharmaceutical ingredient sourced from Canadian equine ranchers in Manitoba and Saskatchewan.

Pfizer Canada generates revenue primarily through one-time prescription medicine sales and vaccine distribution to wholesalers, hospitals, community pharmacies, and public and private drug plans, with pricing determined through pan-Canadian Pharmaceutical Alliance (pCPA) and provincial reimbursement negotiations rather than public disclosure. Its go-to-market combines a direct enterprise field sales force engaging oncologists, cardiologists, specialists, and hospital procurement teams (supported by a dedicated HCP portal at pfizermedicalinformation.ca and a Medical Information call line) with channel distribution through community pharmacies and government public drug plan procurement, plus a humanitarian distribution partnership with Health Partners International of Canada (HPIC) spanning 58 countries. Non-commercial revenue streams include independent medical grants, the annual oncology request-for-proposal grant program (which distributed $900,000 across 14 projects in 2025, with cumulative investment of nearly $4.25 million since 2021), and patient advocacy community investments such as the OOO for Migraine Awareness campaign and long-standing partnerships with the Canadian Paralympic Committee (since 1996) and HPIC (since 1994).

The company serves a horizontally segmented customer base including patients and patient advocacy groups, healthcare professionals, government and public health payers (Health Canada, pCPA, Canadian Drug Agency, provincial drug plans), community pharmacies, and non-profit/community organizations. It addresses structural Canadian healthcare gaps including a 598-day average wait between Health Canada approval and public drug plan listing for cancer treatments (the slowest among G7 nations), rare disease treatment access where only 60% of therapies reach Canada (often up to six years later than the US/Europe), and vaccine equity for older adults. Leadership transitioned in October 2024 with the appointment of An Van Gerven as President of Pfizer Canada, and the Canadian entity is currently positioned to benefit from the parent's December 2023 Seagen acquisition, which brought the PADCEV ADC program into the local portfolio.

Name

Pfizer Canada, Inc

Legal name

Pfizer Canada ULC

Website

https://pfizer.ca

Company type

Private

Founded year

1951

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Pfizer Canada ULC is the Canadian subsidiary of Pfizer Inc., commercializing prescription medicines and vaccines across oncology, infectious disease, women's health, cardiovascular, and rare diseases. It manufactures conjugated estrogens globally at its Brandon, Manitoba facility and distributes via field sales, public drug plans, and community pharmacies in Canada.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Vaccine Programs & Tendering (Government/NGO, Eradication Campaigns) (HLAMAKAO), Equine Therapeutics (Rx) (HLAMAEAC), Travel & Tropical Disease Vaccines (HLAIAEAE)

Keywords

• Prescription pharmaceuticals
• Biopharmaceutical medicines
• Oncology therapeutics
• Vaccine development
• Conjugated estrogens manufacturing

Headquarters

HQ city

Kirkland

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Medicines: Pfizer Canada commercializes a broad portfolio of prescription pharmaceutical products across therapeutic areas including oncology, cardiovascular, rare diseases, inflammatory conditions, and vaccines. Revenue is generated through sales to wholesalers, hospitals, pharmacies, and directly to public and private drug plans upon regulatory approval and reimbursement listing.
2. Vaccines: Pfizer Canada markets and distributes vaccine products including COVID-19, RSV, and other publicly funded vaccines. Revenue flows through public procurement contracts with federal and provincial governments, as well as private market sales.
3. Independent Medical Grants: Pfizer Canada provides independent medical grants to support research, quality improvement, and education initiatives in areas of unmet medical need aligned with Pfizer's therapeutic interests. This represents a non-commercial community investment stream.
4. Oncology Grant Program: Pfizer Canada's annual request-for-proposal (RFP) oncology program distributes grant funding to researchers and organizations addressing gaps in Canadian oncology care. In 2025, $900,000 was distributed across 14 projects. Since 2021, nearly $4.25 million has funded over 45 projects.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

Pfizer Canada ULC develops, manufactures, and commercializes prescription medicines and vaccines across therapeutic areas including oncology (PADCEV, BRAFTOVI), cardiovascular, rare diseases, inflammatory conditions, infectious diseases, and women's health (PREMARIN family of conjugated estrogens). The Brandon, Manitoba facility handles global production of conjugated estrogens active pharmaceutical ingredients sourced from Canadian equine ranchers. Revenue is generated through sales to wholesalers, hospitals, community pharmacies, and public/private drug plans after Health Canada regulatory approval and reimbursement listing.

Product overview

Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. The company operates with a diversified healthcare portfolio consisting of prescription medicines and vaccines. The innovative portfolio focuses on discovery and development of new medicines and vaccines, while also offering a comprehensive portfolio of legacy and multisource medicines. Key products include BRAFTOVI® (encorafenib) for metastatic colorectal cancer with BRAF V600E mutation, PADCEV® (enfortumab vedotin) for bladder cancer and muscle-invasive bladder cancer, COVID-19 vaccines (including Omicron KP.2 variant adapted vaccine developed with BioNTech), ABRYSVO™ for RSV prevention in older adults, and the PREMARIN family of conjugated estrogens products manufactured at the Brandon, Manitoba facility. The company also conducts patient advocacy programs including the OOO for Migraine Awareness Campaign.

Differentiator

Problem solved

Functional benefit

Products and services

• BRAFTOVI® (encorafenib) BRAFTOVI® is a BRAF inhibitor indicated for treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation in combination with cetuximab after prior therapy, and for unresectable or metastatic melanoma with BRAF V600 mutation in combination with binimetinib. First Pfizer therapy to receive priority access under Ontario's FAST program.
• PADCEV® (enfortumab vedotin) PADCEV® is an antibody-drug conjugate indicated in combination with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer (MIBC) in patients ineligible for cisplatin-based chemotherapy, and for treatment of unresectable locally advanced or metastatic urothelial cancer.
• Pfizer-BioNTech COVID-19 Vaccine (Omicron KP.2 Variant Adapted) mRNA-based COVID-19 vaccine adapted for the Omicron KP.2 variant, developed with BioNTech and approved by Health Canada for protection against COVID-19.
• ABRYSVO™ ABRYSVO™ is a publicly funded vaccine for respiratory syncytial virus (RSV) prevention in older adults, representing a step towards national RSV prevention in Canada.
• PREMARIN Family (Conjugated Estrogens) PREMARIN family of brands contains conjugated estrogens sourced from Canadian equine ranchers in Manitoba and Saskatchewan. The Brandon manufacturing facility is responsible for global production of conjugated estrogens active pharmaceutical ingredients used in the PREMARIN family of brands.
• DUAVEE / DUAVIVE Prescription medicines containing conjugated estrogens manufactured at Pfizer Canada's Brandon, Manitoba facility.
• Prescription Products and Vaccines Portfolio Pfizer Canada's diversified healthcare portfolio includes prescription medicines and vaccines. The innovative portfolio focuses on discovery and development of new medicines and vaccines, while also offering a comprehensive portfolio of legacy and multisource medicines across therapeutic areas.

Quantifiable outcome

• 598 days average wait from Health Canada approval to public drug plan listing for cancer treatments — the slowest among G7 nations
• +5 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Migraine CanadacoreGTM or Marketing Partner · 1 January 2024Pfizer Canada partners with Migraine Canada on the annual OOO for Migraine Awareness campaign, now in its third year (2026). The partnership educates Canadians on the impact of migraine in the workplace and advocates for greater understanding and workplace accommodations for the over 5 million Canadians living with migraine.
• Migraine QuébeccoreGTM or Marketing Partner · 1 January 2024Pfizer Canada partners with Migraine Québec on the OOO for Migraine Awareness campaign. Migraine Québec is a charity founded in 2014 dedicated to enhancing quality of life for people living with migraine in Québec, working to build a society where they can thrive without limitations or stigmatization.
• Bladder Cancer CanadacoreStrategic or Co-development Partner · 1 January 2024Bladder Cancer Canada receives support through Pfizer Canada's oncology programs and advocacy efforts. Executive Director Michelle Colero commented on the Health Canada approval of PADCEV for muscle-invasive bladder cancer, representing patient perspectives on unmet need.
• Ontario Government (FAST Program)coreStrategic or Co-development Partner · 1 January 2024Ontario's Ministry of Health launched the Funding Accelerated for Specific Treatments (FAST) program to reduce time from Health Canada approval to public coverage for high-priority oncology medicines. Pfizer's BRAFTOVI became the first Pfizer therapy to be funded under this program.
• Astellas Pharma (PADCEV Collaboration)coreStrategic or Co-development Partner · 1 January 2023Seagen (now Pfizer) and Astellas entered a clinical collaboration to evaluate PADCEV (enfortumab vedotin) in combination with Merck's KEYTRUDA (pembrolizumab) across bladder cancer disease stages. Pfizer completed its acquisition of Seagen on December 14, 2023, bringing the PADCEV program into Pfizer's portfolio.
• Merck & Co. (KEYTRUDA Collaboration)coreStrategic or Co-development Partner · 1 January 2023Merck provides KEYTRUDA (pembrolizumab) for combination therapy with Pfizer's PADCEV in bladder cancer treatment. The collaboration covers perioperative to previously untreated metastatic urothelial cancer stages. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
• Canadian Cardiovascular SocietyminorStrategic or Co-development Partner · 1 January 2023Pfizer collaborates with the Canadian Cardiovascular Society and Canadian Heart Function Alliance to fund research awards addressing heart failure and empowering Indigenous communities to close gaps in cardiovascular health outcomes. Part of Pfizer's commitment to Indigenous health research.
• Tent Partnership for RefugeescoreStrategic or Co-development Partner · 1 January 2021Pfizer Canada works with Tent, an organization that supports the economic inclusion of refugees and displaced peoples. Pfizer's Refugee Leadership Initiative, established in 2021, includes a commitment to hiring refugees and mentoring them. The initiative aims to provide mentorship opportunities to 300 refugees globally between 2022-2025.
• Plan International CanadaminorGTM or Marketing Partner · 1 January 2021Pfizer Canada partners with Plan International Canada's Girls Belong Here program, which sends self-identifying girls and young women aged 14-24 to participate in a full day with leaders across civil, corporate, academic, and government sectors. Pfizer Canada hosted student Candice at their Montreal office for International Women's Day 2023.
• Colorectal Cancer CanadacoreStrategic or Co-development Partner · 1 January 2021Colorectal Cancer Canada is a recipient of Pfizer Canada's oncology grant program. The organization advocates for improved access to colorectal cancer treatments and was quoted in announcements about BRAFTOVI's FAST program listing in Ontario.
• Colorectal Cancer Resource & Action Network (CCRAN)coreStrategic or Co-development Partner · 1 January 2021CCRAN receives support from Pfizer Canada's oncology grant program and serves as a key advocacy partner for colorectal cancer patients in Canada. CCRAN's National Patient Programs Manager was featured in Pfizer's patient access advocacy content.
• BioNTechcoreStrategic or Co-development Partner · 1 January 2020Pfizer and BioNTech entered into a global collaboration to develop and distribute the first authorized COVID-19 vaccine. Pfizer Canada received Health Canada approval for the Omicron KP.2 variant-adapted COVID-19 vaccine. In 2022, Pfizer produced more COVID-19 vaccine doses than any other manufacturer globally.
• Canadian Paralympic Committee (CPC)coreGTM or Marketing Partner · 1 January 1996Pfizer Canada and the Canadian Paralympic Committee have maintained a long-standing partnership since 1996, celebrating 30 years in 2026. Pfizer Canada supports Para athletes through funding, internships, and health and inclusion promotion. The partnership was celebrated at the ParaTough Cup in Montreal.
• Health Partners International of Canada (HPIC)coreStrategic or Co-development Partner · 1 January 1994Pfizer Canada has partnered with HPIC since 1994 to improve access to medicine in developing countries. Pfizer Canada donates millions of dollars in medicines each year for humanitarian kits and missions. This partnership has delivered over $70 million worth of life-saving medicines to vulnerable communities across 58 countries. HPIC is the only Canadian organization licensed to export medicines to other countries.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Merck Canada: Canadian subsidiary of Merck & Co. (MSD), one of the largest biopharmaceutical companies in Canada. Direct peer in oncology (KEYTRUDA), vaccines, and primary care; also a collaboration partner with Pfizer on PADCEV combinations.
• Eli Lilly Canada: Canadian subsidiary of Eli Lilly, a major multinational biopharma. Direct competitor in oncology, immunology, migraine, and rare diseases; Pfizer and Lilly compete head-to-head on migraine awareness platforms and prescriber engagement.
• Johnson & Johnson Innovative Medicine Canada: Canadian pharmaceutical arm of J&J. Direct competitor in oncology, immunology, and pulmonary hypertension, with overlapping prescriber base, hospital sales channels, and pCPA reimbursement dynamics.
• Roche Canada: Canadian arm of F. Hoffmann-La Roche, a global biopharmaceutical leader. Direct competitor in oncology, with overlapping portfolios in lung, breast, and hematologic cancers; also competes in diagnostics-adjacent therapeutics.
• AstraZeneca Canada: Canadian operation of AstraZeneca, a global biopharma. Direct competitor in oncology, respiratory, and vaccines (including RSV, where it competes with ABRYSVO), and a collaboration partner on PADCEV through Astellas.
• Sanofi Canada: Canadian operation of Sanofi, a global biopharmaceutical company. Direct competitor in vaccines (including RSV and influenza where it overlaps with ABRYSVO), rare diseases, and specialty care; similar pCPA negotiation footprint.
• Bristol-Myers Squibb Canada: Canadian subsidiary of BMS, a major biopharmaceutical company. Direct competitor in oncology (immuno-oncology, hematology), cardiovascular, and immunology, competing for the same oncologist and hospital channels.
• AbbVie Canada: Canadian operation of AbbVie, a global biopharma. Direct competitor in immunology, oncology, and neuroscience; competes with Pfizer's oncology and inflammatory pipeline for the same specialist physician audience and reimbursement listings.
• GlaxoSmithKline (GSK) Canada: Canadian subsidiary of GSK, a major vaccines and biopharma player. Direct competitor in vaccines (including RSV, where it competes with ABRYSVO), specialty medicines, and HIV, with parallel public-procurement channels.
• Novartis Pharmaceuticals Canada: Canadian subsidiary of Novartis, a major multinational biopharma. Direct competitor across oncology, cardiovascular, immunology, and rare diseases, with overlapping prescriber base and reimbursement pathway competition via pCPA negotiations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/pfizerca
• YouTubeyoutube.com/%40pfizercanada
• Facebookfacebook.com/pfizer.canada
• LinkedInlinkedin.com/company/pfizer
• Instagraminstagram.com/pfizercanada

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pfizer Canada, Inc